Thursday March 9, 5:58 pm Eastern Time
Company Press Release
Celsion Corporation Makes Application for NASDAQ SmallCap Listing
COLUMBIA, Md.--(BUSINESS WIRE)--March 9, 2000--Celsion Corporation (OTC BB: CELN) today announced that it has applied for listing on the Nasdaq SmallCap market. Based on recent developments, the Company believes that it will meet all the financial and other requirements for listing.
``Moving to the Nasdaq SmallCap market is a logical step for Celsion; a result of the steady progress the Company has made over the last couple of years,' stated Spencer J. Volk, Celsion's President and Chief Executive Officer. ``Through our relationships with medical centers and universities such as Duke University Medical Center and MIT we have developed treatments for cancer and other diseases using focused microwave heat. The steady progress of our Phase I trials for both breast cancer and BPH (benign prostatic hyperplasia) will move us closer to FDA approval. .'
Volk continued, ``The proposed listing on Nasdaq SmallCap will place Celsion in a new league of investment possibilities, including increased attention from analysts and greater exposure to the national and international investment community.' While the Company believes that it has met all the necessary requirements, approval remains at the discretion of Nasdaq.
About Celsion: Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused heat technology delivered by patented microwave technology. Celsion has research or commercial associations with leading institutions such as Duke University, Harbor UCLA Medical Center, MIT, and Montifiore Medical Center.
Forward-looking statements in this release are made pursuant to the ``safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
